| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Carcinogenesis |
Laboratory of Cellular Carcinogenesis and Tumor Promotion, National Cancer Institute, Bethesda, Maryland 20892-4255
| ABSTRACT |
|---|
|
|
|---|
cDNA, RAR
403, with strong RAR dominant negative activity prevented the increase in tyrosine phosphate, suggesting that RAR signaling is involved in RA-induced tyrosine phosphorylation. Tyrosine phosphorylation was induced the most by the RAR-
(193836), followed by RAR-
(194433), but was not significantly induced by RAR-ß (193174)-selective retinoids. This study demonstrates a coordinated albeit relatively late effect of RA on cell adhesion and tyrosine phosphorylation in ER+ human breast cancer cells and suggests RAR-
as the major responsible retinoid receptor. | INTRODUCTION |
|---|
|
|
|---|
Retinoids have also been shown to regulate cell adhesion (13)
, which plays a central role in diverse cellular events, including cellular differentiation, development, and the process of carcinogenesis. The organization of cell adhesion sites is directed by a family of transmembrane receptors known as integrins, which are heterodimeric transmembrane receptors comprised of
and ß subunits, which physically link the ECM to the cytoplasmic actin cytoskeletal network and may function to transmit signals from the ECM to the cytoplasm (14)
. FAK, a cytosolic tyrosine kinase localized in focal adhesion plaques, plays a central role in integrin-mediated signal transduction (15)
. Considerable evidence suggests that enhanced protein tyrosine phosphorylation occurs during focal adhesion plaque formation, and that this phenomenon is mediated through transmembrane integrin molecules. A specific tyrosine residue within another focal adhesion protein, paxillin, has been identified as a primary target for phosphorylation by FAK (16)
. FAK and paxillin also demonstrate a high stoichiometry of tyrosine phosphorylation upon integrin activation (17
, 18)
. Additionally, the increased tyrosine phosphorylation of FAK and/or paxillin have been found to be responsive to a variety of stimuli, including lysophosphatidic acid (19)
, angiotensin II (20)
, sphingosine (21)
, platelet-derived growth factor (22)
, hepatocyte growth factor (23)
, nerve growth factor (24)
, and the neuropeptides bombesin, endothelin, and vasopressin (25
, 26)
.
Our previous results showed that RA can increase integrin ß1 synthesis in F9 teratocarcinoma cells (13)
and down-regulate the expression of fibronectin in NIH-3T3 cells (8)
. This work led us to identify the possible regulatory effects of RA on integrin signaling. In this study, we have demonstrated RA induction of tyrosine phosphorylation and then identified FAK and paxillin as the major proteins showing RA-induced tyrosine phosphorylation in ER+ but not ER- human breast carcinoma cells. We also show that RAR-
and RAR-
-selective retinoids are active in this pathway in MCF-7 human breast cancer cells.
| MATERIALS AND METHODS |
|---|
|
|
|---|
Cell Lines and Cell Culture.
ER+ human breast cancer cell lines MCF-7, ZR-75-1, and T-47D and ER- cell lines MDA-MB-231, MDA-MB-453, and MDA-MB-468 were obtained from the American Type Culture Collection (Rockville, MD) and routinely maintained in DMEM supplemented with 10% FBS in a humidified atmosphere containing 5% CO2 at 37°C.
Retinoid Treatment.
Human breast cancer cells were seeded onto cell culture dishes and kept in DMEM with 10% FBS for 24 h. The medium was changed to 0.5% FCS-containing DMEM, and the cells were incubated for an additional 24 h and then treated with 1 µM (or as specified) all-trans-RA (Sigma) or RAR-selective retinoids (RXR-selective SR11237 was obtained from Dr. Keiko Ozato, NIH, Bethesda, MD) as indicated or with DMSO for the indicated time.
Cell Attachment Assay.
Measurements of cell attachment were done as described previously (27)
. Cells (5 x 105) were grown in 10-cm (diameter) dishes in DMEM with 10% FBS for 24 h. The medium was then changed to 0.5% FCS-containing DMEM, and the cells were grown in this medium for an additional 16 h before treatment with 1 x 10-6 M RA or the solvent DMSO for different times up to 72 h. Cells (2.5 x 104) in 100 µl of medium were added to each well of 96-microwell culture clusters precoated with fibronectin (Dickson) and incubated at 37°C for 1, 2, 3, 4, and 5 h. After removing unattached cells, each well was rinsed with PBS, and 10 µg of fluorogenic substrate 4-methyl-umbelliferylheptanoate (Sigma)/100 µl were added. The cell culture plates were incubated at 37°C for 30 min, followed by measurement by using a Dynatech Instruments Microfluor Reader.
Western Blotting.
RA- or DMSO-treated cells were washed and lysed in Laemmli buffer without reducing agent and bromphenol blue. Whole cell lysates were boiled for 5 min and centrifuged to remove insoluble cell debris. Protein concentration was determined by the bicinchoninic acid method (Pierce). ß-Mercaptoethanol and saturated solution bromphenol blue were added to the samples at a 1% final concentration. Equal amounts of protein were then loaded onto 415% polyacrylamide gels. The proteins were transferred to supported nitrocellulose membrane on a Bio-Rad electroblot apparatus. For the detection of phosphotyrosine, the blots were incubated in 3% nonfat milk in PBS at room temperature for 1 h with constant agitation. The anti-Tyr(P) antibody was used at 1 µg/ml in 2% milk, and the blots were incubated at 4°C overnight. For the detection of other proteins, the blots were blocked at 4°C using 5% nonfat milk overnight in TBS [50 mM Tris-HCl (pH 7.4) and 150 mM NaCl]. Monoclonal anti-FAK or paxillin antibody was used at different dilutions in 2% milk, and the blots were incubated at room temperature for 2 h. The blots were washed three times and incubated for 2 h with horseradish peroxidase-conjugated secondary antibodies at a 1:2000 dilution in TBS. The enhanced chemiluminescence Western blotting system was used to detect the immunoreactive bands. Densitometric evaluation of Western blot analysis was performed with a Molecular Dynamic Research densitometer.
Immunoprecipitation.
RA- or DMSO-treated cells were washed with ice-cold PBS and lysed with ice-cold modified RIPA buffer [50 mM Tris-HCl (pH 7.4), 150 mM NaCl, 1% NP40, 0.25% sodium deoxycholate, 1 mM EGTA, 1 mM phenylmethylsulfonyl fluoride, 1 mM sodium orthovanadate and sodium fluoride, and 1 µg/ml aprotinin, leupeptin, and pepstatin]. Lysates were clarified by centrifugation at 15,000 x g for 10 min and precleared by incubation with protein A-agarose at 4°C for 1 h. After the removal of protein A-agarose by a brief (10 s) centrifugation, the supernatants were transferred to tubes for immunoprecipitation. Immunoprecipitation was routinely performed by adding 4 µg of polyclonal anti-FAK or monoclonal anti-paxillin antibody to 250 µg of lysates (in 500 µl of RIPA buffer). The reaction mixture was incubated at 4°C for 1 h, and 50 µl of protein A-agarose beads were added to the mixture, followed by incubation at 4°C overnight on a rotary shaker. The immunoprecipitates were washed three times with ice-cold RIPA buffer and collected by a microcentrifuge pulse, and the proteins were extracted with 50 µl of 2x Laemmli sample buffer. The samples were electrophoretically separated on SDS-polyacrylamide 415% gradient gels and immunoblotted with anti-FAK, paxillin, or Tyr(P) antibody.
Infection of MCF-7 Cells with Retroviral Vectors.
The retroviral vector LXRAR
403SN, in which a truncated RAR-
gene is inserted into the retroviral vector LXSN, was a gift from Dr. Steven J. Collins (28
, 29)
. Cells were seeded at 50% confluence into 100-mm dishes. The next day, they were infected with the LXSN or LXRAR
SN retroviral vector in the presence of 4 µg/ml Polybrene (8)
. After an overnight incubation, the medium was replaced, and cells were grown for 48 h before G418 (1 mg/ml) was added. G418-resistant cells were isolated.
Northern blot analysis was used to identify LXRAR
SN- or LXSN-transfected cell clones. The full-length fragments of the RAR-
were excised from the expression plasmid pSG5-RAR-
. Isolation of total RNA was performed by using TRIzol LS reagent from Life Technologies, Inc. Total RNA (20 µg) was fractionated on a 1% agarose gel and blotted overnight onto Schleicher & Schuell nitrocellulose. The membrane was prehybridized for 5 h at 42°C in a prehybridization solution of 6x SSC, 5x Denhardts reagent, 0.5% SDS, 100 µg/ml denatured fragmented salmon sperm DNA, and 50% formamide. The probes (5 x 106 cpm/ml) were boiled and added to the prehybridization buffer, and the membranes were hybridized for 24 h at 42°C. After washing, autoradiography was performed on Kodak X-Omat AR film using double intensifying screens.
| RESULTS |
|---|
|
|
|---|
|
|
An additional approach was to use MCF-7 cells expressing the RAR
403 construct transduced by a retroviral vector. Fig. 3
shows that the infected cells express the typical 4.7-kb retroviral transcript containing the RAR
403 mRNA. This construct functions as a dominant negative against RAR-mediated responses (28
, 29) . RA did not increase tyrosine phosphorylation in the dominant negative RAR
403-transfected MCF-7 cells (Fig. 4A)
, whereas RA could still increase tyrosine phosphorylation in the control LXSN vector-transfected MCF-7 cells (Fig. 4B)
. These results indicate that tyrosine phosphorylation in MCF-7 cells is mediated by RAR.
|
|
-selective retinoid 193836 was the most effective stimulator, followed by the RAR-
- selective 194433. In contrast, the RAR-ß-selective 193174 was without significant activity.
FAK and Paxillin Are the Major Proteins Showing RA-induced Tyrosine Phosphorylation.
We were interested in identifying the major proteins showing RA-induced tyrosine phosphorylation. For this purpose, we chose several proteins with Mr around 125,000 and 68,000 as the candidates. Anti-c-Src (Mr 60,000), Fyn (Mr 59,000), and Lyn (Mr 56,000) antibodies were chosen to immunoprecipitate the proteins with Mr around 68,000 and detect their tyrosine phosphorylation. Anti-JAK1 (Mr 130,000), retinoblastoma protein (pRB; Mr 110,000), and vinculin (Mr 116,000) were chosen to immunoprecipitate the proteins with Mr around 125,000 and detect their tyrosine phosphorylation. No obvious increase in tyrosine phosphorylation of those proteins at the indicated time points was found after RA treatment (data not shown). Immunoprecipitation of FAK and paxillin was followed by immunoblotting with the respective antibody used for immunoprecipitation to detect the expression of FAK and paxillin. The results from Fig. 5, A and B
, show that RA has no obvious effect on FAK and paxillin expression at 12 and 24 h. In sharp contrast, tyrosine phosphorylation of FAK (Fig. 5B)
and paxillin (Fig. 5D)
increased by 2.8- and 2.9-fold at 12 and 24 h, respectively, for FAK (Fig. 6B)
and by 2.1- and 4-fold for paxillin (Fig. 6D)
. These experiments were conducted on cell lysates that were immunoprecipitated with anti-FAK or paxillin antibody, followed by immunoblotting with anti-Tyr(P) antibody. The results presented above demonstrate that FAK and paxillin are major proteins showing a RA-induced tyrosine phosphorylation in MCF-7 cells. However, the phosphorylation of other proteins is likely, especially because only a single band is observed in Fig. 5
, whereas a doublet was observed in Fig. 2
.
|
|
| DISCUSSION |
|---|
|
|
|---|
FAK plays a central role in integrin-mediated signal transduction (15)
and may also act as an important molecule in the action of oncogenic variants of pp60SRC and mitogenic neuropeptides (21)
. Tyrosine phosphorylation of FAK can be stimulated by several different mechanisms. For example, cell adhesion to ECM ligands can induce tyrosine phosphorylation of FAK (32)
, as can the clustering of integrins induced by anti-integrin antibodies (33)
. In platelets, the thrombin-induced tyrosine phosphorylation of FAK is dependent on integrin-mediated platelet aggregation (34)
. Paxillin is a major phosphotyrosyl protein in chicken embryo fibroblasts and during rat embryonic development, and, like FAK, it is localized to focal adhesions (18)
. Tyrosine phosphorylation of paxillin and FAK is coordinately regulated in intact cells (25
, 35)
, and FAK immunoprecipitates can induce the tyrosine phosphorylation of purified preparations of paxillin (36)
. The neuropeptide bombesin has been shown to rapidly increase the tyrosine phosphorylation of FAK and paxillin in Swiss 3T3 cells through a mechanism that is independent of both protein kinase C and the mobilization of intracellular Ca2+ (25
, 26)
. Platelet-derived growth factor and sphingosine, a potential breakdown product of all sphingolipids, can also induce FAK and paxillin tyrosine phosphorylation in Swiss 3T3 cells (22)
. Nerve growth factor, hepatocyte growth factor, angiotensin II, and bradykinin can also induce the FAK and/or paxillin tyrosine phosphorylation in different cells (20, 21, 22, 23, 24)
. Interestingly, insulin was found to stimulate tyrosine dephosphorylation of FAK (37)
. The induction of FAK and paxillin tyrosine phosphorylation by the factors mentioned above is rapid. In contrast, RA did not show tyrosine phosphorylation induction for at least 3 h. Induction, however, was reproducibly detected at 12 and 24 h. The reason for this relatively late response and the mechanism by which RA induces FAK and paxillin tyrosine phosphorylation have yet to be determined. Many of the actions of retinoids are mediated through two classes of nuclear receptors, RARs and RXRs, as well as by cytoplasmic binding proteins (cellular retinoic acid-binding proteins and CRBPs). The RARs and RXRs act as ligand-inducible transcription factors that can increase the transcription of direct target genes by binding to cis-acting RA response elements on DNA (38)
. Several studies demonstrated that ER+ human breast carcinoma cell lines and tumor samples exhibit significantly higher levels of RAR-
than their ER- counterparts. ER+ human breast carcinoma cell lines are sensitive, and ER- cell lines are resistant to growth-inhibitory effects of RA (39
, 40)
. Retinoid-resistant ER- human breast carcinoma MDA-MB-231 cells transfected with RAR-
acquired sensitivity to growth inhibition by retinoids (41)
. These results suggested that RAR-
may have great importance in mediating RA growth-inhibitory effects in breast cancer cells. In this work, RAR mediation of the RA-induced tyrosine phosphorylation is also demonstrated. The introduction of a mutated RAR-
(RAR
403), which has strong dominant-negative activity on the RAR-mediated signaling pathways, abolished the RA induction of tyrosine phosphorylation in MCF-7 cells. Furthermore the RXR-selective compound, SR11237, was unable to induce tyrosine phosphorylation in MCF-7 cells. The expression of the RAR-
gene was not sufficient to reestablish RA-induced tyrosine phosphorylation in RA-refractory ER- MDA-MB-231 cells (data not shown). Our data show that RAR-
and RAR-
-selective retinoids are at least as active as RA in eliciting the tyrosine-phosphorylation response; however, RAR-ß does not appear to be involved.
The delayed response suggests that RA may first modulate the expressions of its direct target genes, such as growth factors or other signal transducers, and induce the tyrosine phosphorylation of FAK and paxillin as a result of these or related primary events. However, under similar culture conditions, RA inhibits the cell growth of ER+ but not ER- breast cancer cells. The cell growth inhibition is accompanied by a marked down-regulation of cyclin D3 (42) expression (19, 62, and 83% inhibition at 24, 48, and 72 h, respectively), simultaneous with the reduced expression of the retinoblastoma protein pRB and its phosphorylated form and of CDK4 and E2F1. Significant inhibition of cell growth is observed at 72 h of RA treatment, but not at 24 and 48 h of RA treatment. Therefore, the marked stimulation of FAK and paxillin tyrosine phosphorylation appears to precede the observed down-regulation of cyclin D3, CDK4, pRB as well as E2F1 proteins and the observed inhibition of cell growth and increase in cell adhesion that could not be detected before 72 h. Therefore, we conclude that RA-induced tyrosine phosphorylation may be a responsible factor in the cascade that leads to the inhibition of cell growth and increased adhesion and apoptosis.
Finally, it is also of interest that a very recent report (43) has shown that RA augments mitogen-activated protein/extracellular signal-regulated kinase-dependent mitogen-activated protein kinase activation needed to elicit HL-60 cell differentiation and growth arrest. Obviously, several phosphorylation pathways signal downstream of the retinoid receptors.
| ACKNOWLEDGMENTS |
|---|
403SN and Dr. Keiko Ozato for the RXR-selective SR11237. | FOOTNOTES |
|---|
1 Present address: Department of Biochemistry and Molecular Biology, University of Maryland at Baltimore, Baltimore, MD 21201. ![]()
2 Present address: Allergan, Inc., 2525 Dupont Drive, Irvine, CA 92623. ![]()
3 To whom requests for reprints should be addressed, at Laboratory of Cellular Carcinogenesis and Tumor Promotion, National Cancer Institute, NIH, Building 37, Room 3A-17, 37 Convent Drive, Bethesda, MD 20892-4255. Phone: (301) 496-2698; Fax: (301) 496-8709; E-mail: luigi_de_luca{at}nih.gov ![]()
4 The abbreviations used are: RAR, retinoic acid receptor; ER, estrogen receptor; RA, retinoic acid; FAK, focal adhesion kinase; RXR, retinoid X receptor; ECM, extracellular matrix; FBS, fetal bovine serum; RIPA, radioimmunoprecipitation assay; CRBP, cellular retinol-binding protein. ![]()
Received 1/16/98. Accepted 10/29/98.
| REFERENCES |
|---|
|
|
|---|
proteins in NIH-3T3 cells: block of this response by ras transformation. J. Biol. Chem., 271: 6502-6508, 1996.
exhibiting dominant-negative activity alters the lineage development of a multipotent hematopoietic cell line. Genes Dev., 6: 2258-2269, 1992.
acquire sensitivity to growth inhibition by retinoids. J. Biol. Chem., 269: 21440-21447, 1994.This article has been cited by other articles:
![]() |
A. Gattelli, M. N. Zimberlin, R. P. Meiss, L. H. Castilla, and E. C. Kordon Selection of Early-Occurring Mutations Dictates Hormone-Independent Progression in Mouse Mammary Tumor Lines J. Virol., November 15, 2006; 80(22): 11409 - 11415. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Rousseau, J. N. Nichol, F. Pettersson, M.-C. Couture, and W. H. Miller Jr. ER{beta} Sensitizes Breast Cancer Cells to Retinoic Acid: Evidence of Transcriptional Crosstalk Mol. Cancer Res., September 1, 2004; 2(9): 523 - 531. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. M. Karp, H. Pan, M. Zhang, D. J. Buckley, L. A. Schuler, and A. R. Buckley Identification of HRPAP20: A Novel Phosphoprotein that Enhances Growth and Survival in Hormone-Responsive Tumor Cells Cancer Res., February 1, 2004; 64(3): 1016 - 1025. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. A. Antonyak, J. E. Boehm, and R. A. Cerione Phosphoinositide 3-Kinase Activity Is Required for Retinoic Acid-induced Expression and Activation of the Tissue Transglutaminase J. Biol. Chem., April 19, 2002; 277(17): 14712 - 14716. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Watanabe, M. Kurabayashi, M. Arai, K. Sekiguchi, and R. Nagai Combined effect of retinoic acid and basic FGF on PAI-1 gene expression in vascular smooth muscle cells Cardiovasc Res, July 1, 2001; 51(1): 151 - 159. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Fukunaka, T. Saito, K. Wataba, K. Ashihara, E. Ito, and R. Kudo Changes in expression and subcellular localization of nuclear retinoic acid receptors in human endometrial epithelium during the menstrual cycle Mol. Hum. Reprod., May 1, 2001; 7(5): 437 - 446. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |